UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $340.0375, but opened at $320.89. UCB shares last traded at $338.24, with a volume of 4 shares.

Wall Street Analyst Weigh In

Several analysts have issued reports on UCBJF shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a report on Monday, December 8th. Barclays reaffirmed an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th. Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

UCB Trading Down 0.5%

The firm’s 50-day moving average price is $304.20 and its 200-day moving average price is $276.83. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.